Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Bulevirtide (Hepcludex)

decorative image of the issue cover

Published May 1, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Bulevirtide (Hepcludex), 2 mg, powder for solution for injection, subcutaneous.
  • Indication: For the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.